HAE Relative Valuation
HAE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HAE is overvalued; if below, it's undervalued.
Historical Valuation
Haemonetics Corp (HAE) is now in the Undervalued zone, suggesting that its current forward PE ratio of 16.20 is considered Undervalued compared with the five-year average of 21.39. The fair price of Haemonetics Corp (HAE) is between 126.50 to 185.09 according to relative valuation methord. Compared to the current price of 83.81 USD , Haemonetics Corp is Undervalued By 33.75%.
Relative Value
Fair Zone
126.50-185.09
Current Price：83.81
33.75%
Undervalued
16.20
PE
1Y
3Y
5Y
Trailing
Forward
10.75
EV/EBITDA
Haemonetics Corp. (HAE) has a current EV/EBITDA of 10.75. The 5-year average EV/EBITDA is 13.71. The thresholds are as follows: Strongly Undervalued below 5.48, Undervalued between 5.48 and 9.59, Fairly Valued between 17.82 and 9.59, Overvalued between 17.82 and 21.94, and Strongly Overvalued above 21.94. The current Forward EV/EBITDA of 10.75 falls within the Historic Trend Line -Fairly Valued range.
13.04
EV/EBIT
Haemonetics Corp. (HAE) has a current EV/EBIT of 13.04. The 5-year average EV/EBIT is 17.74. The thresholds are as follows: Strongly Undervalued below 7.83, Undervalued between 7.83 and 12.78, Fairly Valued between 22.69 and 12.78, Overvalued between 22.69 and 27.65, and Strongly Overvalued above 27.65. The current Forward EV/EBIT of 13.04 falls within the Historic Trend Line -Fairly Valued range.
2.83
PS
Haemonetics Corp. (HAE) has a current PS of 2.83. The 5-year average PS is 3.23. The thresholds are as follows: Strongly Undervalued below 1.27, Undervalued between 1.27 and 2.25, Fairly Valued between 4.21 and 2.25, Overvalued between 4.21 and 5.18, and Strongly Overvalued above 5.18. The current Forward PS of 2.83 falls within the Historic Trend Line -Fairly Valued range.
13.67
P/OCF
Haemonetics Corp. (HAE) has a current P/OCF of 13.67. The 5-year average P/OCF is 12.65. The thresholds are as follows: Strongly Undervalued below -4.13, Undervalued between -4.13 and 4.26, Fairly Valued between 21.03 and 4.26, Overvalued between 21.03 and 29.42, and Strongly Overvalued above 29.42. The current Forward P/OCF of 13.67 falls within the Historic Trend Line -Fairly Valued range.
15.98
P/FCF
Haemonetics Corp. (HAE) has a current P/FCF of 15.98. The 5-year average P/FCF is 10.31. The thresholds are as follows: Strongly Undervalued below -10.44, Undervalued between -10.44 and -0.06, Fairly Valued between 20.68 and -0.06, Overvalued between 20.68 and 31.06, and Strongly Overvalued above 31.06. The current Forward P/FCF of 15.98 falls within the Historic Trend Line -Fairly Valued range.
Haemonetics Corp (HAE) has a current Price-to-Book (P/B) ratio of 4.61. Compared to its 3-year average P/B ratio of 4.48 , the current P/B ratio is approximately 3.00% higher. Relative to its 5-year average P/B ratio of 4.79, the current P/B ratio is about -3.59% higher. Haemonetics Corp (HAE) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 3.62%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 2.97% , the current FCF yield is about -100.00% lower.
4.61
P/B
Median3y
4.48
Median5y
4.79
6.68
FCF Yield
Median3y
3.62
Median5y
2.97
Competitors Valuation Multiple
The average P/S ratio for HAE's competitors is , providing a benchmark for relative valuation. Haemonetics Corp Corp (HAE) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -5.27%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of HAE increased by 7.34% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 9.79 to 11.82.
The secondary factor is the Revenue Growth, contributed -5.27%to the performance.
Overall, the performance of HAE in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Haemonetics Corp (HAE) currently overvalued or undervalued?
What is Haemonetics Corp (HAE) fair value?
How does HAE's valuation metrics compare to the industry average?
What is the current P/B ratio for Haemonetics Corp (HAE) as of Dec 05 2025?
What is the current FCF Yield for Haemonetics Corp (HAE) as of Dec 05 2025?
What is the current Forward P/E ratio for Haemonetics Corp (HAE) as of Dec 05 2025?